A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Condition: Schizophrenia Intervention: Drug: Paliperidone Palmitate 3-Month Formulation (PP3M) Sponsor: Janssen-Cilag International NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2019 Category: Research Source Type: clinical trials
